Viking Global Investors
Viking Global Investors is an investment firm that uses fundamental analysis to select investments across industries and geographies.
Business Model:
Revenue: $15M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Viking Global Investors Information
Geographic Data
Address: 55 Railroad Avenue
City: Greenwich
State: CT
Zip: 06830
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
1,562,596Website Global Rank
16,000Website Monthly Traffic
Twitter Followers
Description
Viking Global Investors is an investment firm that uses fundamental analysis to select investments across industries and geographies. It is a global investment firm managing more than twenty billion in capital across long-short equity and long-only strategies. The firm was established in 1999 and is headquartered in Greenwich, Connecticut, with offices in New York City, Hong Kong, and London.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2019 | Ginkgo Bioworks | Series E | 0 |
| 5/2020 | Ginkgo Bioworks | Series F | 70M |
| 10/2020 | Dock | Private Equity Round | 170M |
| 6/2015 | Credit Karma | Series E | 175M |
| 1/2021 | Color | Series D | 167M |
| 4/2021 | Druva | Series H | 147M |
| 7/2020 | Mantra Bio | Series A | 25M |
| 5/2019 | Impossible Foods | Series E | 300M |
| 8/2019 | MedAnswers | Seed Round | 5M |
| 3/2020 | Impossible Foods | Series F | 500M |
| 1/2022 | Standard BioTools | Post-IPO Equity | 0 |
| 1/2021 | Resilient Biotics | Series A | 7.2M |
| 4/2014 | Adaptive Biotechnologies | Series C | 5M |
| 9/2017 | Joyn Bio | Series A | 0 |
| 3/2018 | Joyn Bio | Series A | 0 |
| 10/2018 | Genomatica | Equity | 90M |
| 3/2019 | Mediphage Bioceuticals | Convertible Note | 3.5M |
| 12/2017 | Ginkgo Bioworks | Series D | 0 |
| 5/2020 | Apeel Sciences | Series D | 0 |
| 2/2022 | Cazoo | Post-IPO Debt | 0 |
| 12/2021 | DermBiont | Series A | 0 |
| 4/2014 | Birchbox | Series B | 60M |
| 7/2016 | Roivant Sciences | Private Equity Round | 500M |
| 6/2021 | Motif | Series B | 0 |
| 8/2019 | Motif | Series A | 27.5M |
| 6/2018 | Checkerspot | Seed Round | 5M |
| 8/2021 | Apeel Sciences | Series E | 0 |
| 7/2018 | Apeel Sciences | Series C | 70M |
| 11/2016 | Prospect Bio | Seed Round | 0 |
| 4/2019 | NextGen Jane | Series A | 9M |
| 10/2016 | Biome Makers | Seed Round | 2.2M |
| 5/2022 | Locus Biosciences | Series B | 0 |
| 12/2019 | Iterable | Series D | 60M |
| 6/2023 | Ecovative Design | Series E | 30M |
| 8/2021 | Biome Makers | Series B | 0 |
| 10/2022 | Arctic Wolf | Convertible Note | 401M |
| 6/2020 | 4D Molecular Therapeutics | Series C | 0 |
| 10/2020 | Arctic Wolf | Series E | 200M |
| 6/2019 | DermBiont | Series A | 0 |
| 8/2017 | Auris Health | Series D | 0 |
| 11/2018 | Auris Health | Series E | 0 |
| 10/2021 | Arcaea | Series A | 78M |
| 12/2017 | Zentalis Pharmaceuticals | Series B | 34M |
| 7/2017 | Vets First Choice | Private Equity Round | 223M |
| 12/2019 | Zentalis Pharmaceuticals | Series C | 85M |
| 9/2017 | BridgeBio Pharma | Series C | 135M |
| 3/2021 | ID.me | Series C | 0 |
| 4/2023 | ID.me | Series D | 0 |
| 9/2021 | AlphaSense | Series C | 180M |
| 4/2023 | AlphaSense | Series D | 100M |
| 4/2020 | Rallybio | Series B | 0 |
| 10/2020 | Allonnia | Series A | 40M |
| 12/2021 | Mythic Therapeutics | Series B | 0 |
| 2/2017 | Xcell Biosciences | Series A | 12M |
| 6/2009 | Vivacta | Venture Round | 4.5M |
| 9/2021 | Astarte Medical | Series A | 0 |
| 6/2021 | Clip | Series D | 250M |
| 6/2021 | PROCEPT BioRobotics | Series G | 0 |
| 8/2021 | Algen Biotechnologies | Seed Round | - |
| 2/2018 | PROCEPT BioRobotics | Series E | 0 |
| 2/2020 | TruGenomix | Seed Round | 0 |
| 1/2020 | Color | Series D | 75M |
| 4/2022 | Revenova | Venture Round | 0 |
| 1/2023 | Mantra Bio | Series A | 9M |
| 10/2021 | Patina | Series A | 50M |
| 8/2017 | aTyr Pharma | Post-IPO Equity | 45M |
| 4/2014 | Adaptive Biotechnologies | Series D | 100M |
| 7/2015 | Ginkgo Bioworks | Series B | 0 |
| 11/2020 | VastBiome | Seed Round | 4.5M |
| 8/2021 | Talkdesk | Series D | 230M |
| 11/2020 | Pharvaris | Series C | 80M |
| 10/2020 | LianBio | Series A | 0 |
| 3/2020 | Cloudbeds | Series C | 0 |
| 4/2019 | Checkerspot | Series A | 13M |
| 5/2019 | Inhibrx | Private Placement | 40M |
| 2/2016 | Vitagene | Seed Round | 2M |
| 12/2020 | Edgewise Therapeutics | Series C | 95M |
| 7/2021 | Arctic Wolf | Series F | 150M |
| 7/2021 | Sema4 | Post-IPO Equity | 350M |
| 10/2020 | Solarea Bio | Series A | 11.2M |
| 5/2023 | Solarea Bio | Series B | 0 |
| 7/2020 | Talkdesk | Series C | 143M |
| 8/2020 | PMV Pharmaceuticals | Series D | 70M |
| 5/2022 | Dock | Private Equity Round | 0 |
| 10/2018 | Talkdesk | Series B | 100M |
| 10/2021 | Roivant Sciences | Post-IPO Equity | 0 |
| 6/2020 | HeadLight | Series B | 25.6M |
| 4/2020 | Affinivax | Series B | 120M |
| 6/2021 | Antheia | Series B | 0 |
| 8/2021 | Pepgen | Venture Round | 0 |
| 7/2016 | Trace Genomics | Seed Round | 4M |
| 1/2021 | Affinivax | Series C | 226M |
| 11/2018 | Roivant Sciences | Private Equity Round | 0 |
| 9/2022 | RayzeBio | Series D | 160M |
| 6/2017 | Yes To | Equity | 56M |
| 6/2019 | Viela Bio | Series B | 0 |
| 12/2022 | Pearl Health | Series B | 0 |
| 7/2021 | Genomatica | Series C | 0 |
| 9/2018 | 4D Molecular Therapeutics | Series B | 0 |
| 2/2021 | Ensoma | Series A | 0 |
| 11/2021 | Color | Series E | 100M |
| 1/2022 | Xcell Biosciences | Series B | 27.5M |
| 8/2021 | Zentera Therapeutics | Series B | 75M |
| 2/2018 | Boost Biomes | Seed Round | 2M |
| 2/2021 | Day One Biopharmaceuticals | Series B | 130M |
| 1/2015 | Moderna Therapeutics | Series E | 0 |
| 12/2022 | Vector Biomed | Venture Round | 15M |
| 6/2022 | AlphaSense | Series D | 225M |
| 1/2019 | BridgeBio Pharma | Equity | 299.2M |
| 4/2021 | Lightmatter | Series B | 80M |
| 5/2020 | Checkerspot | Series B | 36M |
| 1/2023 | Ensoma | Series B | 0 |
| 10/2021 | Groove | Series B | 45M |
| 2/2016 | EpiBiome | Series A | 6M |
| 4/2021 | Icosavax | Series B | 0 |
| 1/2023 | SetPoint Medical | Venture Round | 0 |
| 9/2015 | Impossible Foods | Series D | 108M |
| 8/2015 | Editas Medicine | Series B | 0 |
| 8/2020 | Kinnate Biopharma | Series C | 98M |
| 12/2020 | RayzeBio | Series B | 105M |
| 6/2020 | Athira Pharma | Series B | 85M |
| 6/2016 | Ginkgo Bioworks | Series C | 0 |
| 3/2021 | Ecovative Design | Series D | 60M |
| 4/2021 | Atlast Food | Series A | 40M |
| 7/2020 | VelosBio | Series B | 137M |
| 10/2020 | Talaris Therapeutics | Series B | 0 |
| 5/2021 | Nuvalent | Series B | 0 |
| 6/2021 | RayzeBio | Series C | 108M |
| 6/2021 | Iterable | Series E | 0 |
| 7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
| 11/2019 | PMV Pharmaceuticals | Series C | 0 |
| 1/2022 | Cognism | Series C | 0 |
| 10/2019 | Algen Biotechnologies | Pre Seed Round | - |
| 2/2018 | Moderna Therapeutics | Series G | 0 |
| 11/2007 | Vivacta | Series B | 12M |
| 12/2020 | Boost Biomes | Series A | 2M |
| 6/2017 | Deciphera Pharmaceuticals | Series C | 52M |
| 6/2019 | Druva | Series G | 0 |
| 5/2023 | Lightmatter | Series C | 0 |
| 10/2021 | Global Processing Services | Private Equity Round | 300M |
| 3/2021 | Amunix | Series B | 117M |
| 2/2020 | Polaris Genomics | Seed Round | 2M |
| 3/2019 | Astarte Medical | Series A | 0 |
| 4/2018 | Eidos Therapeutics | Series B | 0 |
| 3/2020 | AbCellera Biologics | Series A | 75M |
| 11/2021 | Cloudbeds | Series D | 0 |
| 5/2020 | AbCellera | Series B | 105M |
| 6/2022 | AlphaSense | Series D | 0 |
| 5/2022 | Locus Biosciences | Series B | 0 |
| 5/2022 | Dock | Private Equity Round | 0 |
| 4/2022 | Revenova | Venture Round | 0 |
| 2/2022 | Cazoo | Post-IPO Debt | 0 |
| 1/2022 | Standard BioTools | Post-IPO Equity | 0 |
| 1/2022 | Xcell Biosciences | Series B | 0 |
| 1/2022 | Cognism | Series C | 0 |
| 12/2021 | DermBiont | Series A | 0 |
| 12/2021 | Mythic Therapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
